Group 1: Novartis - Novartis is a strong long-term investment candidate due to its innovative pipeline and diversified product offerings, with 10 products generating over $1 billion in sales each as of September 30 [4][5] - The company has shown resilience against patent cliffs, with a revenue increase of 8% year-over-year to $13.9 billion and earnings per share of $2.25, which is 9% higher than the previous year [6][7] - Novartis has a solid dividend history, increasing payouts for 28 consecutive years, currently offering a forward yield of 3%, significantly higher than the S&P 500 average of 1.2% [10] Group 2: Shopify - Shopify has experienced a 50% stock increase this year, driven by strong financial results and a vision to build a sustainable 100-year company [11] - The platform is a leader in the e-commerce market, providing customizable templates and a range of services that facilitate efficient business operations for merchants [12] - Shopify's market share grew from 10% at the end of 2023 to 12% by the end of 2024, benefiting from high switching costs for merchants [14] - The company has improved its profitability, achieving net income in three out of the last four quarters, positioning itself well for continued dominance in the e-commerce sector [15]

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

President Donald Trump on Friday unveiled a sweeping set of drug-pricing agreements with nine major pharmaceutical companies, presenting the initiative as a cornerstone of his effort to bring American medicine costs closer to those paid in Europe.The announcement marked a significant expansion of the administration’s pricing push, with Trump confirming that deals have now been struck with 14 of the 17 drugmakers he formally pressed in July to lower prices. Central to the strategy is the launch of a new dire ...

Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid p ...

US President Donald Trump on Friday (December 19) announced agreements with nine major pharmaceutical companies to sharply cut the prices of medicines sold through the government’s Medicaid program and to cash-paying consumers, marking his latest push to bring US drug costs in line with those in other wealthy nations.The deals were unveiled at a White House press conference, where Trump appeared alongside senior executives from the participating drugmakers.“We were subsidizing the entire world. We’re not do ...

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price ...

US President Donald Trump is expected to announce new agreements on Friday (December 19) aimed at lowering prescription drug prices, the White House said. The announcement is scheduled for 1 p.m. ET at the White House.AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among the major pharmaceutical companies expected to participate, Reuters reporting citing sources familiar with the matter.Swiss drugmakers Novartis and Roche are also reportedly part of the deals, according to Bloomberg News.Backgr ...

以下文章来源于凤凰WEEKLY ，作者凯斯 凤凰WEEKLY . 有温度、有情感、有趣味 来源丨凤凰weekly（ID： phoenixweekly)） 作者丨凯斯 编辑丨章鱼 图源丨Midjourney 印度做题家，正在批量成为「美国 CEO 」。 据统计，在去年的《财富》500强企业里，大约 有10%的CEO都是印度裔 。 而在全球排名前300个公司里，有 超过6成都选用了印度裔的高管 。这些公司包括但不限于谷歌、微软、Adobe、百事、德勤、星巴克、诺华、麦肯锡、 香奈儿...... 在全球各大商业领域，印度人都爬到了顶点。 而实现这一切，他们仅仅花了不到30年—— 1997年， 拉马尼·艾尔开始掌舵哈特福德保险公司，成了史上第一位印度裔的500强的CEO；现如今，就像美国驻印大使的开玩笑所说的那样："如果你不 是个印度人，就没法在美国当上CEO。" 为什么在欧美的职场，印度人能晋升得如此之快？ 有英文世界的商业网站总结称：印度裔能成事儿，主要是因为他们都接受了优秀的教育，有着推崇勤奋和毅力、重视团队合作的价值观...... 从这里走出来的，不止有当下微软的掌舵人，还有Adobe、宝洁、万事达卡等一大堆 ...

Market Overview - The S&P 500 index has experienced four consecutive declines, primarily driven by large technology stocks[1] - Major U.S. indices collectively fell, with the Nasdaq down nearly 2%[9] - The S&P 500 closed at 6,800, reflecting a decline of 1.16% for the day and a year-to-date increase of 14.28%[3] Hong Kong Market Performance - The Hong Kong stock market showed a significant recovery in the afternoon, with major indices rebounding after two consecutive days of decline[9] - Large technology stocks such as Meituan and Kuaishou rose nearly 2%, while Tencent and Alibaba increased over 1%[9] - The financial sector saw a collective rise, with China Life Insurance up over 4% and CITIC Securities up over 3%[9] Sector Highlights - Precious metals stocks strengthened, with China Silver Group rising over 7% due to a weaker dollar and expectations of interest rate cuts, pushing silver prices above $66 per ounce[9] - The aviation sector saw gains, with China Southern Airlines up over 5% as ticket bookings surged ahead of the New Year holiday[9] - The lithium battery sector also rose, driven by a significant increase in lithium carbonate futures prices, with Tianqi Lithium up 5.83%[9] Economic Indicators - Japan's November exports grew by 6.1% year-on-year, exceeding market expectations, with a trade surplus of 322.2 billion yen[13] - The U.S. Treasury yields have shown fluctuations, impacting market sentiment and investment strategies[18]

诺华制药表示，公司正与特朗普政府进行磋商，并致力于寻找降低美国民众用药成本、解决美国与其他 高收入国家之间价格差距的方案。诺华制药表示："我们认为，所有国家都应该对创新成本给予应有的 重视并公平分担，以便世界各地的患者都能及时受益。" 罗氏在一份声明中表示，公司支持特朗普降低药品成本的目标，并鼓励其他国家奖励生物制药创新。该 公司表示："我们致力于与政府和政策制定者合作，制定可持续的解决方案，以保护创新并保障患者护 理。" 特朗普7月致函17家制药公司，敦促它们大幅降低药品价格。辉瑞(PFE.US)和阿斯利康(AZN.US)率先达 成协议，同意降低处方药价格，以换取关税减免。上个月，礼来(LLY.US)和诺和诺德(NVO.US)达成协 议，大幅降低美国联邦医疗保险(Medicare)、医疗补助(Medicaid)以及自费患者的常用GLP-1减肥药的价 格。 智通财经APP获悉，瑞士制药巨头诺华制药(NVS.US)和罗氏周四表示支持美国降低药品价格的努力， 并正与特朗普政府合作，朝着这一目标努力。此前有报道称，两家公司已接近达成价格协议。一位知情 人士透露，涉及这两家制药公司的药品定价协议可能即将达成，但他拒绝 ...